Lenz Therapeutics is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss and $225 million in cash on hand at close. The merger marks an end for Graphite Bio, which launched in 2020...
Kite, the Gilead subsidiary specializing in CAR-T, is trying out epigenetic editing as it seeks new ways to create next-generation cell therapies that are more effective against cancer. Teaming up with California-based Epic Bio, Kite will tap its new partner’s...
https://doi.org/10.1038/s41467-023-41829-y An exciting study published in Nature Communications on October 4, 2023, authored by Zhao, L., Koseki, S.R.T., Silverstein, R.A., et al., delves into overcoming limitations in CRISPR genome editing by introducing SpRYc—a...
In a strategic move beyond liver-focused therapies, Intellia Therapeutics and Regeneron Pharmaceuticals have announced the expansion of their CRISPR collaboration. Following their 2016 partnership, the two companies achieved a milestone in 2021 with first-in-human...
Researchers from the Guangzhou Institutes of Biomedicine and Health have grown human-like kidneys in pigs. Chinese scientists have succeeded in growing kidneys containing human cells in pig embryos, a world first that could one day help address organ donation...
